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Hypophysitis is a frequent toxic endocrine side-effect of immunotherapy. Prevalence is
higher with anti-CTLA-4 antibodies (4-20%) or in association with PD-1 inhibitors (8%).
Diagnosis is presumptive, based on poorly specific clinical symptoms (usually,
headache and asthenia) and/or hyponatremia and/or at least one pituitary deficit
and/or abnormal imaging. Visual disorder or polyuropolydipsic syndrome are
exceptional. In decreasing order of frequency, deficits are thyrotropic (86-100%),
gonadotropic (85-100%) or corticotropic (50-73%); somatotropin deficit or abnormal
prolactin level are rarer. Pituitary MRI in acute phase shows variable moderate
increase in pituitary volume, ruling out differential diagnoses, especially pituitary
metastasis. Treatment of corticotropin deficiency requires systematic emergency
replacement therapy, with the usual modalities, while treatment of other deficits
depends on clinical status and progression. Thyrotropin and gonadotropin deficits
usually recover, but corticotropin deficiency persists over the long term, requiring
education and specialized endocrinologic follow-up. Onset of hypophysitis does not
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